Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Connect Biopharma Holdings Limited (NASDAQ: CNTB ) recently shared positive topline results from its global Phase 2 study. The clinical-stage biopharmaceutical company revealed that rademikibart, its next-generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, demonstrated significant efficacy as an add-on trea